Active Ingredient History

  • Now
Saracatinib (AZD-0530) is an experimental drug being developed by AstraZeneca. It acts as a dual kinase inhibitor, with selective actions as a Src inhibitor and a Bcr-Abl tyrosine-kinase inhibitor.   Wikipedia

  • SMILES: CN1CCN(CCOc2cc(OC3CCOCC3)c4c(Nc5c(Cl)ccc6OCOc56)ncnc4c2)CC1
  • Mol. Mass: 542.04
  • ALogP: 3.94
  • ChEMBL Molecule:
More Chemistry
4-quinazolinamine, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1- piperazinyl)ethoxy)-5-((tetrahydro-2h-pyran-4-yl)oxy)- | az-10353926 | azd0530 | azd 0530 | azd-0530 | azd0530 difumarate | n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1-piperazinyl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)-4-quinazolinamine | n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)quinazolin-4-amine | n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-((tetrahydro- 2h-pyran-4-yl)oxy)quinazolin-4-amine bi((2e)-but-2-enedioate) | saracatinib | saracatinib difumerate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue